Research and Markets: Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors 2014 Report
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/thm6kp/competitor) has announced the addition of the "Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors" report to their offering.
“Competitor Analysis: VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors”
The present Competitive Intelligence Report about VEGF Antibodies - Bevacizumab and Ranibizumab Biosimilars and Biosuperiors provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) used to treat various cancers and ophthalmic diseases.
The first generation of recombinant antibodies targeting VEGF consists of bevacizumab (Avastin) from Roche (Genentech) and ranibizumab (Lucentis) from Roche (Genentech) and Recently, VEGF-Trap Eye originating from Regeneron Pharmaceuticals has been approved for cancer and ophthalmic indications. Combined sales of all four VEGF targeting products were US$ 13,192 mln in 2013, of which 53.4% were from oncology sales.
The commercial success of the VEGF antibodies and the expiry of patent protection has laid the ground for development of second generation biobetter or biosuperior molecules as well as of biosimilar copies of the originator products.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies for treatment of cancer and neo-angiogenic eye diseases. In addition, the report lists company-specific R&D pipelines of VEGF antibodies. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target / Mechanism of Action,
- Class of Compound,
- Product Category,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
Key Topics Covered
Table of Contents
1. Bevacizumab Biosimilars and Biosuperiors Marketed VEGF Antibodies
- Avastin Sales & Pipeline
- Zaltrap Sales & Pipeline
Next Generation Avastin Pipeline
- Anti-VEGF Antibody Pipeline
- Anti-VEGF-Receptor Antibody Pipeline
- Bispecific Anti-VEGF Antibody Pipeline
Avastin Biosimilar Pipeline
2. Ranibizumab Biosimilars and Biosuperiors Marketed VEGF Antibody
- Lucentis Sales & Pipeline
- Eylea Sales & Pipeline
Next Generation Lucentis Pipeline
Lucentis Biosimilar Pipeline
3. Corporate VEGF Antibody Biosimilar & Biobetter Pipelines
For more information visit http://www.researchandmarkets.com/research/thm6kp/competitor
About Research and Markets
Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products.